Exploring of Primate Models of Tick-Borne Flaviviruses Infection for Evaluation of Vaccines and Drugs Efficacy

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Pripuzova, Natalia S ^a,b   Gmyl, Larissa V ^a   Romanova, Lidiya Iu ^a   Tereshkina, Natalia V ^a   Rogova, Yulia V ^a   Terekhina, Liubov L ^a   Kozlovskaya, Liubov I ^a   Vorovitch, Mikhail F ^a   Grishina, Karina G ^a   Timofeev, Andrey V ^a   Karganova, Galina G ^a  

^a CHUMAKOV INSTITUTE OF POLIOMYELITIS AND VIRAL ENCEPHALITIDES   (Russian Federation)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INACTIVATED VIRUS VACCINE; NEUTRALIZING ANTIBODY; TICK BORNE ENCEPHALITIS VACCINE; VIRUS RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ANTIVIRAL THERAPY; ARTICLE; CERCOPITHECUS; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFICACY; FEMALE; HEMOLYTIC ANEMIA; IMMUNIZATION; INFECTION PREVENTION; INFECTION SENSITIVITY; MACACA FASCICULARIS; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; OMSK HEMORRHAGIC FEVER; THROMBOCYTOPENIA; TICK BORNE ENCEPHALITIS; TICK BORNE ENCEPHALITIS FLAVIVIRUS; VIREMIA; VIRUS INACTIVATION; VIRUS NEUTRALIZATION; VIRUS STRAIN; VIRUS TITRATION;

ANIMALS; ANTIBODIES, VIRAL; CENTRAL NERVOUS SYSTEM; CERCOPITHECUS AETHIOPS; DISEASE MODELS, ANIMAL; ENCEPHALITIS VIRUSES, TICK-BORNE; ENCEPHALITIS, TICK-BORNE; HOST SPECIFICITY; HUMANS; LYMPH NODES; MACACA FASCICULARIS; MALE; SPLEEN; TREATMENT OUTCOME; VACCINATION; VIRAL VACCINES;

ANIMALIA; ARBOVIRUS; CERCOPITHECUS AETHIOPS; IXODIDA; MACACA FASCICULARIS; OMSK HEMORRHAGIC FEVER VIRUS; PRIMATES; TICK-BORNE ENCEPHALITIS VIRUS;

EID: 84876065676     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0061094     Document Type: Article

References (48)

1. Suss J, (2011) Tick-borne encephalitis 2010: epidemiology, risk areas, and virus strains in Europe and Asian overview. Ticks Tick Borne Dis 2: 2-15.
2. Onishchenko GG, Fedorov IuM, Pakskina ND, (2007) [Organization of supervision of tick-borne encephalitis and ways of its prevention in the Russian Federation]. Vopr Virusol 52 (5):: 8-10.
3. Pattnaik P, (2006) Kyasanur forest disease: an epidemiological view in India. Rev Med Virol 16: 151-165.
4. Ebel GD, (2010) Update on Powassan virus: emergence of a North American tick-borne flavivirus. Annu Rev Entomol 55: 95-110.
5. Ruzek D, Yakimenko VV, Karan LS, Tkachev SE, (2010) Omsk haemorrhagic fever. Lancet 376: 2104-2113.
6. Vorob'eva MS, Rasshchepkina MN, Ladyzhenskaia IP, (2007) [Vaccines, immunoglobulins, and test systems for the prevention and diagnosis of tick-borne encephalitis]. Vopr Virusol 52: 30-36.
7. Mansfield KL, Johnson N, Phipps LP, Stephenson JR, Fooks AR, et al. (2009) Tick-borne encephalitis virus- a review of an emerging zoonosis. J Gen Virol 90: 1781-1794.
8. Romanenko VV, Esiunina MS, Kiliachina AS, (2007) [Experience in implementing the mass immunization program against tick-borne encephalitis in the Sverdlovsk Region]. Vopr Virusol 52: 22-25.
9. Andersson CR, Vene S, Insulander M, Lindquist L, Lundkvist A, et al. (2010) Vaccine failures after active immunisation against tick-borne encephalitis. Vaccine 28: 2827-2831.
10. Pletnev AG, Bray M, Huggins J, Lai CJ, (1992) Construction and characterization of chimeric tick-borne encephalitis/dengue type 4 viruses. Proc Natl Acad Sci U S A 89: 10532-10536.
11. Pletnev AG, Karganova GG, Dzhivanyan TI, Lashkevich VA, Bray M, (2000) Chimeric Langat/Dengue viruses protect mice from heterologous challenge with the highly virulent strains of tick-borne encephalitis virus. Virology 274: 26-31.
12. Mandl CW, (2004) Flavivirus immunization with capsid-deletion mutants: basics, benefits, and barriers. Viral Immunol 17: 461-472.
13. Kofler RM, Heinz FX, Mandl CW, (2004) A novel principle of attenuation for the development of new generation live flavivirus vaccines. Arch VirolSuppl: 191-200.
14. Aberle JH, Aberle SW, Kofler RM, Mandl CW, (2005) Humoral and cellular immune response to RNA immunization with flavivirus replicons derived from tick-borne encephalitis virus. J Virol 79: 15107-15113.
15. Rumyantsev AA, Chanock RM, Murphy BR, Pletnev AG, (2006) Comparison of live and inactivated tick-borne encephalitis virus vaccines for safety, immunogenicity and efficacy in rhesus monkeys. Vaccine 24: 133-143.
16. Rumyantsev AA, Murphy BR, Pletnev AG, (2006) A tick-borne Langat virus mutant that is temperature sensitive and host range restricted in neuroblastoma cells and lacks neuroinvasiveness for immunodeficient mice. J Virol 80: 1427-1439.
17. Engel AR, Rumyantsev AA, Maximova OA, Speicher JM, Heiss B, et al. (2010) The neurovirulence and neuroinvasiveness of chimeric tick-borne encephalitis/dengue virus can be attenuated by introducing defined mutations into the envelope and NS5 protein genes and the 3′ non-coding region of the genome. Virology 405: 243-252.
18. Pripuzova NS, Tereshkina NV, Gmyl LV, Dzhivanyan TI, Rumyantsev AA, et al. (2009) Safety evaluation of chimeric Langat/Dengue 4 flavivirus, a live vaccine candidate against tick-borne encephalitis. J Med Virol 81: 1777-1785.
19. Omori-Urabe Y, Yoshii K, Ikawa-Yoshida A, Kariwa H, Takashima I, (2011) Needle-free jet injection of DNA and protein vaccine of the far-eastern subtype of tick-borne encephalitis virus induces protective immunity in mice. Microbiol Immunol 55 (12):: 893-7.
20. Engel AR, Mitzel DN, Hanson CT, Wolfinbarger JB, Bloom ME, et al. (2011) Chimeric tick-borne encephalitis/dengue virus is attenuated in Ixodes scapularis ticks and Aedes aegypti mosquitoes. Vector Borne Zoonotic Dis 11 (6):: 665-74.
21. Heiss BL, Maximova OA, Thach DC, Speicher JM, Pletnev AG, (2012) MicroRNA targeting of neurotropic flavivirus: effective control of virus escape and reversion to neurovirulent phenotype. J Virol 86 (10):: 5647-59.
22. Bollati M, Alvarez K, Assenberg R, Baronti C, Canard B, et al. (2011) Structure and functionality in flavivirus NS-proteins: perspectives for drug design. Antiviral Res 87 (2):: 125-48.
23. Levanov LN, Matveev LE, Goncharova EP, Lebedev LR, Ryzhikov AB, et al. (2011) Chimeric antibodies against tick-borne encephalitis virus. Vaccine 28 (32):: 5265-71.
24. Achazi K, Patel P, Paliwal R, Radonić A, Niedrig M, et al. (2012) RNA interference inhibits replication of tick-borne encephalitis virus in vitro. Antiviral Res 93 (1):: 94-100.
25. Morris JA, O'Connor JR, Smadel JE, (1955) Infection and immunity patterns in monkeys injected with viruses of Russian spring-summer and Japanese encephalitis. Am J Hyg 62: 327-341.
26. Slonim D, Simon J, Zavadova H, (1966) Pathogenicity of tick-borne encephalitis virus. VII. Relation between infective and pathogenic activity for rhesus monkeys. Acta Virol 10: 413-419.
27. Pogodina VV, Frolova MP, Malenko GV, Fokina GI, Levina LS, et al. (1981) Persistence of tick-borne encephalitis virus in monkeys. I. Features of experimental infection. Acta Virol 25: 337-343.
28. Hambleton P, Stephenson JR, Baskerville A, Wiblin CN, (1983) Pathogenesis and immune response of vaccinated and unvaccinated rhesus monkeys to tick-borne encephalitis virus. Infect Immun 40: 995-1003.
29. Mandl CW, (2005) Steps of the tick-borne encephalitis virus replication cycle that affect neuropathogenesis. Virus Res 111: 161-174.
30. Ilyenko VI, Pokrovskaya OA, (1960) Characteristics of the course of experimental infection in monkeys inoculated with tick-borne and bi-phasic encephalitis and louping ill viruses. Acta Virol 4: 75-81.
31. Zlotnik I, Smith CE, Grant DP, Peacock S, (1970) The effect of immunosuppression on viral encephalitis, with special reference to cyclophosphamide. Br J Exp Pathol 51: 434-439.
32. Frolova MP, Pogodina VV, (1984) Persistence of tick-borne encephalitis virus in monkeys. VI. Pathomorphology of chronic infection in central nervous system. Acta Virol 28: 232-239.
33. Suss J, Gelpi E, Klaus C, Bagon A, Liebler-Tenorio EM, et al. (2007) Tick-borne encephalitis in naturally exposed monkey (Macaca sylvanus). Emerg Infect Dis 13: 905-907.
34. Nathanson NHB, (1966) Experimental infections of monkeys with Langat virus. I. Comparison of viremia following peripheral inoculation of Langat and Japanese encephalitis viruses. Am J Epidemiol 84: 541-556.
35. Dubov A (1969) Live vaccine against tick-borne encephalitis. Tyumen: Tyumen Scientific Research Institute of Regional Infectious Pathology. 161 p.
36. Pletnev AG, Bray M, Hanley KA, Speicher J, Elkins R, (2001) Tick-borne Langat/mosquito-borne dengue flavivirus chimera, a candidate live attenuated vaccine for protection against disease caused by members of the tick-borne encephalitis virus complex: evaluation in rhesus monkeys and in mosquitoes. J Virol 75: 8259-8267.
37. Dubov A (1971) Trying out experience of the live vaccine against tick-borne encephalitis. Tyumen: Tyumen Scientific Research Institute of Regional Infectious Pathology. 172 p.
38. Smorodintsev AA, Dubov AV (1986) Tick-borne encephalitis and its prevention. Leningrad-Moscow: AMS USSR. 321 p.
39. Monath TP, Soike K, Levenbook I, Zhang ZX, Arroyo J, et al. (1999) Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates. Vaccine 17: 1869-1882.
40. Kozlovskaya LI, Osolodkin DI, Shevtsova AS, Romanova L, Rogova YV, et al. (2010) GAG-binding variants of tick-borne encephalitis virus. Virology 398: 262-272.
41. Ecker M, Allison SL, Meixner T, Heinz FX, (1999) Sequence analysis and genetic classification of tick-borne encephalitis viruses from Europe and Asia. J Gen Virol 80: 179-85.
42. Reed LJ, Muench H, (1938) A simple method of estimating fifty percent endpoints. The American Journal of Hygiene 493-497: 493-497.
43. Romanova L, Kozlovskaia LI, Shevtsova AS, Karganova GG, (2006) [Evidence for the absence of tick-borne encephalitis virus RNA in bioassays]. Vopr Virusol 51: 38-41.
44. Puchhammer-Stöckl E, Kunz C, Mandl CW, Heinz FX, (1995) Identification of tick-borne encephalitis virus ribonucleic acid in tick suspensions and in clinical specimens by a reverse transcription-nested polymerase chain reaction assay. Clin Diagn Virol 4 (4):: 321-6.
45. Nathanson N, Goldblatt D, Thind IS, Davis M, Price WH, (1965) Histological studies of the monkey neurovirulence of group B arboviruses. I. A semiquantitative grading scale. Am J Epidemiol 82: 359-381.
46. Levenbook IS, Pelleu LJ, Elisberg BL, (1987) The monkey safety test for neurovirulence of yellow fever vaccines: the utility of quantitative clinical evaluation and histological examination. J Biol Stand 15: 305-313.
47. Zlontnik I, Grant DP, Carter GB, (1976) Experimental infection of monkeys with viruses of the tick-borne encephalitis complex: degenerative cerebellar lesions following inapparent forms of the disease or recovery from clinical encephalitis. Br J Exp Pathol 57: 200-210.
48. El'bert LB, Gagarina AV, Khanina MK, Krutianskaia GL, Grachev VP (1980) [Concentrated purified vaccine against tick-borne encephalitis prepared by means of zonal ultracentrifugation. Development of the preparation]. Vopr Virusol: 341-345.